Evidence of brain target engagement in Parkinson’s disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials

Evidence of brain target engagement in Parkinson’s disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials

Abstract Background Impaired brain energy metabolism has been observed in many neurodegenerative diseases, including Parkinson’s disease (PD) and multiple sclerosis (MS). In both diseases, mitochondrial dysfunction and energetic impairment can lead to neuronal dysfunction and death. CNM-Au8® is a su...

Full description

Bibliographic Details
Main Authors: Jimin Ren, Richard B. Dewey, Austin Rynders, Jacob Evan, Jeremy Evan, Shelia Ligozio, Karen S. Ho, Peter V. Sguigna, Robert Glanzman, Michael T. Hotchkin, Benjamin M. Greenberg
Format: Article
Language:English
Published: BMC 2023-12-01
Series:Journal of Nanobiotechnology
Subjects:
Catalytic gold nanotherapeutic
Target engagement
Drug development
Parkinson’s Disease
Multiple sclerosis
Neuroimaging
Online Access:https://doi.org/10.1186/s12951-023-02236-z

Internet

https://doi.org/10.1186/s12951-023-02236-z

Similar Items